Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10017321HBVENSG00000198648.12protein_codingSTK39NoNo27347Q9UEW8
TVIS30000837HIVENSG00000198648.12protein_codingSTK39NoNo27347Q9UEW8
TVIS30016971HIVENSG00000198648.12protein_codingSTK39NoNo27347Q9UEW8
TVIS30087580HIVENSG00000198648.12protein_codingSTK39NoNo27347Q9UEW8
TVIS20007805HPVENSG00000198648.12protein_codingSTK39NoNo27347Q9UEW8
TVIS20033217HPVENSG00000198648.12protein_codingSTK39NoNo27347Q9UEW8
TVIS20054804HPVENSG00000198648.12protein_codingSTK39NoNo27347Q9UEW8
TVIS20037698HPVENSG00000198648.12protein_codingSTK39NoNo27347Q9UEW8
TVIS20054957HPVENSG00000198648.12protein_codingSTK39NoNo27347Q9UEW8
TVIS20054772HPVENSG00000198648.12protein_codingSTK39NoNo27347Q9UEW8
TCGA Plot Options
Drug Information
GeneSTK39
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009391
UniProt IDQ9UEW8
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830